8-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

NT 10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

NT 10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

S-8 - Greenwich LifeSciences, Inc. (0001799788) (Filer)

8-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

DEFA14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)

DEF 14A - Greenwich LifeSciences, Inc. (0001799788) (Filer)

STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment with standard of care HER2/neu targeted therapy to improve invasive breast cancer free survival meets the criteria for Fast Track

STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available here: About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patie

STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more expensive staffing from Clinical Research Organizations (CROs). The strategy to bring in key clinical functions inside the Company is expected to reduce costs over the remaining duration of

STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collecte

STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company's website at the bottom of the Welcome page: https://greenwichlifesciences.com/ Jun 28, 2025 – Interview on Bloomberg TV (recorded April 2025)Jun 4, 2025 – Live Fireside Chat with Research Analyst at Noble Virtual ConferenceApr 29, 2025

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA-A*02 arm was expanded to 250 patients in 2024 with approval from both EU and US regulators. With t

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over tim

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modif

STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date in FLAMINGO-01. Additional safety updates and comparison to the Pha

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types, shows that approximately 46% of all screened patients h

Noble Capital Markets initiated coverage of Greenwich LifeSciences with a rating of Outperform and set a new price target of $45.00

HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00

Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)